$STVN: are oral GLP-1s really a death blow? | Aurelian Research's Leo Trudel

YAVP episode #389

Stevanato (STVN) makes the glass vials and pre-filled syringes that GLP-1 drugs ship in. The stock has sold off on fears that oral GLP-1s replace injectables, but Aurelian Research's Leo Trudel argues that's a misread: biologics demand keeps growing, the mix is shifting toward higher-margin "high-value solutions," and switching costs in regulated drug delivery are real. We dig into the bull case, the oral-vs-injectable debate, capacity and oversupply risk, capital allocation, regulatory lock-in, and what would change Leo's view.

---

This podcast is sponsored by AlphaSense.

Earnings season has always been a test of speed and discipline—but the real challenge isn’t just keeping up. It’s cutting through the noise, tracking what matters across dozens of companies, and turning information into insight before the next call begins. AlphaSense’s AI Playbook for Earnings Season shows how leading investment and corporate strategy teams are using AI-driven workflows to stay ahead—summarizing transcripts instantly, monitoring competitors in real time, and surfacing the metrics that move markets. The difference is how the work gets done. Instead of juggling spreadsheets, notes, and disconnected tools, teams can centralize earnings intelligence, validate consensus with trusted research, and act on signals faster—before opportunities pass. You can download your complimentary copy of The AI Playbook for Earnings Season here. And if you’d like to try AlphaSense for free, request your trial at alpha-sense.com/YAVP.

---

Please follow the podcast on Spotify, iTunes, or YouTube! And please be sure to rate / review the podcast if you enjoy it, or share it with someone else who would enjoy it (more listeners is a critical part of the flywheel that keeps this Substack and podcast going!).

Transcript for paid subs begins below (The initial transcript is AI-generated and is replaced with a professionally edited version when available)

Disclaimer: Nothing on this podcast or on this blog is investing or financial advice; please see our full disclaimer here. The transcript below is from a third party transcription service; it’s entirely possible there are some errors in the transcript.